期刊文献+

12个病种中医临床诊疗指南适用性评价 被引量:9

The Applicability Evaluation on TCM Clinical Diagnosis and Treatment Guidelines of 12 Diseases
原文传递
导出
摘要 目的评价2008年和2012年颁布的12个病种中医临床诊疗指南的适用性。方法采用国家中医药管理局统一设计的中医临床诊疗指南适用性调查问卷,从一般信息、指南质量水平、指南应用情况和意见建议4个方面对2008年与2012年颁布的共12个病种的中医诊疗指南进行调查和统计分析。结果 2012版指南的使用率为91.67%,高于2008版指南的使用率31.67%(P<0.05);2012版指南的质量水平和临床应用情况整体优于2008版指南(P<0.05);使用过指南的医生对指南质量水平和临床应用情况的评价优于未使用过指南的医生(P<0.05);不同职称医生对指南适用性评价的差异无统计学意义(P>0.05)。结论2012版指南更容易被临床医生接受,建议应及时评价指南质量和适用性,及时更新修订,并加大指南的推广力度。 Objective To evaluate the clinical applicability of existing traditional Chinese medicine( TCM) clinical practice guidelines. Method This study was performed with questionnaire survey. A protocol questionnaire designed by State Administration of Traditional Chinese Medicine was adopted to evaluate the clinical applicability of TCM clinical diagnosis and treatment guidelines. The clinical practice guidelines on 12 kinds of diseases promulgated in 2008 and 2012 were investigated,and analyzed with statistical method in respect to the general information,quality,application status and advice / suggestions. Result The application rate of guidelines,2012 edition was 91. 67%,which was higher than of the 2008 edition( 31. 67%,P〈0. 05). Quality level and clinical application rate of 2012 edition was higher than those of the 2008 edition( P〈0. 05). Doctors who have used the guidelines gave more positive assessment on the quality level and clinical application than those who have not yet used them( P〈0. 05). No statistical significant difference shows among doctors with different professional titles( P〉0. 05). Conclusion Clinical guidelines in 2012 edition are more accepted in clinicians. It is suggested that timely quality evaluation and applicability assessment is necessary. Regular updates and better promotion for the guidelines should be performed.
出处 《中医杂志》 CSCD 北大核心 2015年第4期293-296,共4页 Journal of Traditional Chinese Medicine
基金 国家中医药管理局2013年度公共卫生专项[ZYYBZ-2013(PJ29) ZYYBZ-2013(PJ30)] 国家中医药管理局中医临床研究基地业务建设专项(JDZX2012172)
关键词 中医临床指南 适用性评价 统计分析 TCM clinical guidelines applicability evaluation statistical analysis
  • 相关文献

参考文献11

  • 1中华中医药学会.中医内科常见病诊疗指南西医疾病部分[S].北京:中国中医药出版社,2008:64.
  • 2中华中医药学会.中医内科常见病诊疗指南:中医疾病部分[S].北京:中国中医药出版社,2008:53-55.
  • 3中华中医药学会.中医儿科常见病诊疗指南[S].北京:中国中医药出版社,2012:17-20.
  • 4中华中医药学会.中医妇科常见病诊疗指南[S].北京:中国中医药出版社,2012:1513-1514.
  • 5中华中医药学会.中医眼科常见病诊疗指南[S].北京:中国中医药出版社,2012:10-11.
  • 6中华中医药学会.中医皮肤科常见病诊疗指南[S].北京:中国中医药出版社,2012:35.
  • 7宇文亚,韩学杰,谢雁鸣,刘孟宇,史楠楠,王丽颖,吕爱平.中医药标准推广评价初探[J].中医杂志,2012,53(18):1609-1610. 被引量:19
  • 8刘孟宇,赵学尧,王丽颖,史楠楠,宇文亚,戴雪珂,韩学杰,吕爱平.关于中医诊疗指南诊治内容的思考[J].中医杂志,2013,54(21):1823-1826. 被引量:18
  • 9宇文亚,韩学杰,刘孟宇,王丽颖,史楠楠,戴雪珂,吕爱平.基于矩阵模型的中医临床指南辨证论治疗效评价方法探索[J].中华中医药杂志,2012,27(12):3076-3079. 被引量:9
  • 10刘孟宇,王丽颖,周奇,宇文亚,史楠楠,戴雪珂,韩学杰,吕爱平.Q方法在中医诊疗标准制定中的作用探讨[J].中华中医药杂志,2012,27(11):2792-2794. 被引量:5

二级参考文献38

共引文献81

同被引文献96

  • 1丁玉峰,吴方建.药物经济学理论及应用[J].中国药师,2004,7(7):507-510. 被引量:67
  • 2谢雁鸣,朱芸茵,葛继荣,朴海垠,于嘉,王和鸣,陈卫衡,邢美荣.基于临床流行病学调查的原发性骨质疏松症中医基本证候研究[J].世界科学技术-中医药现代化,2007,9(2):38-44. 被引量:59
  • 3Field M J,Lohr K N.Guidelines for clinical practice:from development to use.Washington DC:Institute of Medicine, 1992.
  • 4Hayward R S,Wilson M C,Tunis S R,et al.Users' guides to the medical literature.VIII.How to use clinical practice guidelines. A Are the recommendations valid?The Evidence-Based Medicine Working Group.JAMA, 1995,274(7):570-574.
  • 5Vlayen J,Aertgeerts B,Hannes K,et al.A systematic review of appraisal tools for clinical practice guidelines:multiple similarities and one common deficit.Int J Qual Health Care,2005,17(3):235- 242.
  • 6http://www.agreetrust.org/.
  • 7Watine J.Conflict between Guideline Methodologic Quality and Recommendation Validity:A Potential Problem for Practitioners. Clin Chem,2006,52(1):65-72.
  • 8Roubille C1,Richer V2,Starnino T3.The effects of tumour necrosis factor inhibitors,methotrexate,non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis,psoriasis and psoriatic arthritis:a systematic review and meta-analysis[J].Ann Rheum Dis,2015,74(3):480-489.
  • 9Gulácsi L,Brodszky V,Baji P,et al.Biosimilars for the management of rheumatoid arthritis:economic considerations[J].Expert Rev Clin Immunol,2015,11(1):S43-52.
  • 10Saisho K,Yoshikawa N,Sugata K,et al.Prevalence of chronic kidney disease and administration of RA-related drugs in patients with RA:The Nin Ja 2012 study in Japan[J].Mod Rheumatol,2015,26(3):1-17.

引证文献9

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部